Please login to the form below
colorectal cancer
This page shows the latest colorectal cancer news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda gains two more approvals in Japan
New approvals in breast and colorectal cancer take the number of indication for the immunotherapy mega-blockbuster to 15 in Japan. ... The second indication is in colorectal cancer, targeting unresectable, advanced or recurrent high microsatellite
Latest news
-
NICE recommends Keytruda for colorectal cancer patients with rare mutations
There are currently no specific treatments for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. ... Patients with these mutations face a poorer prognosis as well as a greater risk of death than
-
GSK wins approval for anti-PD-1 antibody Jemperli in endometrial cancer
test. Cells that are mismatch repair (MMR) deficient often have many DNA mutations and are commonly found in colorectal, gastrointestinal and endometrial cancer. ... Endometrial cancer has the highest rate of dMMR among solid tumour types, with
-
AZ showcases data for next-generation PARP inhibitor AZD5305
candidate. “Our data at AACR reflect a robust early-stage pipeline, poised to deliver life-changing medicines to patients living with cancer. ... The ongoing study found that Zn-c3 generated five partial responses (PR), with two confirmed PRs in
-
GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
The majority of this cohort had gastrointestinal cancer, with the highest prevalence in colorectal, gastric and small intestinal cancer. ... This includes in patients with colorectal cancer – participants in this group demonstrated an OOR of 36.2%,
-
Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer
The result underscores our commitment to the colorectal cancer community and we hope that as many people as possible will benefit from this innovative treatment,” she added. ... Over 42, 000 people in the UK are newly diagnosed with colorectal cancer
More from news
Approximately 17 fully matching, plus 226 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... If successful, that would dramatically increase the eligible patient population in breast cancer as well as
-
Pharma deals continue to slide
CAP7.1 prodrug of etoposide at start phase 3 for second line treatment of biliary tract cancer. ... Phase III toll-like receptor 9 agonist for metastatic colorectal cancer. 124.
-
Winning the war against cancer
data sources and the organisation of screening programmes for colorectal cancer. ... Cancer is an important disease to see [its] impact on the health system.
-
Deal Watch September 2016
Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Janssen granted Tracon Pharmaceuticals the rights to
More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
Kite Pharma appoints head of regulatory affairs
colorectal cancer. ... Other recent additions include chief financial officeras chief medical officer; and several cancer experts to the company's scientific advisory board.
-
Boston Biomedical appoints commercial head
colorectal cancer.
-
Mirna hires former Pfizer director as CMO
Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... This background will benefit Mirna, which has just
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Early diagnosis underpins NHS cancer strategy
In addition, Cancer Alliances will also implement a new timed diagnostic pathway for specific cancers, building on the timed pathways already being introduced in lung, colorectal and prostate cancer. ... suspected symptoms to RDCs, supported by the local
-
Artificial Intelligence in healthcare
trust the same digital system to recommend their treatment pathway for a potentially lethal cancer. ... Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment.
-
Lynch syndrome: a patient perspective
My grandfather was probably the first in the family to be afflicted with Lynch syndrome or Hereditary Nonpolyposis Colorectal Cancer (HNPCC). ... colon cancer as a cause of death in families where half their members previously died for the disease.
-
90TEN nominated for five Communiqué Awards
Meanwhile two of the agency’s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- Novartis announces positive phase 3 trial results for advanced oesophageal cancer
- Sanofi Global Health unveils new nonprofit Impact brand
- Pfizer announces commitment to achieve Net-Zero Standard by 2040
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
